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INTRODUCTION
Cancer, which is the uncontrolled growth and 
proliferation of cells due to mutation of genes which 
accelerate cell division rates and evade the pro-
grammed cell death, is the leading cause of death in 
the world. Over the past decade, a number of che-
motherapeutic drugs with different mechanism of 
actions and targeting various stages of metastatic 
cell growth have flooded the pharmaceutical mar-
ket. Based on their mechanism of action, these drugs 
can be classified into different classes as alkylating 
ABSTRACT
In the present work, 25 of novel 1,2,4-triazole(4H) derivatives were evaluated for their anti-tumor activi-
ty through docking studies and antitumor screening in vitro. The target protein structures of 1YS1, 1FM6, 
1BXL were docked with new 1,2,4-triazole(4H) derivatives provided excellent results. In vitro anticancer ac-
tivity of the compounds was tested by the National Cancer Institute and some of them have revealed the an-
ticancer activity on leukemia, melanoma, lung, ovarian cancers cell lines. Among tested compounds three 
samples (3,8,16) showed high antitumor activity level and their in-depth preclinical studies are in progress. 
N-isopropylanilides of 4-benzyl-5-(4-brom)phenoxymethyl-1,2,4-triazolyl-3yl-merkapto-acetic acid 8 was 
found to be the most active candidate.
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agents, antimetabolites, antibiotics, nucleoside an-
alogues, antimitotic agents, etc. However, most of 
these drugs are associated with severe toxicities and 
are not effective against all types of cancer (1). Thus, 
the search for new anticancer drugs and the develop-
ment of more effective treatment strategies continues 
to be imperative.
The 1,2,4-triazole(4H) derivatives, which are 
used in this study, play an important role in me-
dicinal chemistry. Although they have been known 
from long ago to be biologically active, their var-
ied biological features are still of great scientific in-
terest. Their derivatives have a variety of biological 
properties, such as anti-microbial and anti-inflam-
matory (2,3), antidepressant (4), antifungal (5), anti-
convulsant (6), and antitumor properties (7-8). Due 
to their antitumor effect, 1,2,4-triazole(4H) deriv-
atives are attracting more interest. Until now, there 
have been only a few computational studies on 
1,2,4-triazole(4H) derivatives; also, the protein tar-
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gets of 1,2,4-triazole(4H) derivatives have not yet re-
ceived a great deal of attention.
Synthetic strategy of the present study consists 
in structure modification of 1,2,4-triazole(4H) ring 
scaffolds modifying it in the positions 1, 2 and 5 with 
the aim of obtaining more potent pharmacological-
ly active compounds. Several key types of the reac-
tions were generally used us that allowed to obtain 
25 new 1,2,4-triazole(4H) derivatives. The synthet-
ic methods used to prepare the highly functionalized 
1,2,4-triazole(4H)  and related derivatives depicted 
in Table 1 can be found in previously reported work 
(9-12).  
The computer prognosis of biological activity 
spectrum of all new compound synthesized by pro-
gram PASS has set that the several substances 1-25 
are able to show the inhibitor of cell growth activity 
(13,14). We have selected those substances for further 
studies. They are shown in Table 1.
MATERIALS AND METHODS
Molecular docking and antitumor screening of 
25 new 1,2,4-triazole(4H) derivatives has been per-
formed. Molecular docking is a key tool in structur-
al molecular biology and computer assisted drug de-
sign. The goal of ligand-protein docking is to predict 
the predominant binding mode(s) of a ligand with 
a protein of known three-dimensional structure. A 
large number of targets are under exploration for 
chemotherapeutic treatments for cancer. NSAIDs in-
hibited the expression of the anti-apoptotic protein 
Bcl-X
L
, resulting in an altered ratio of BAX to Bcl-X
L
 
and subsequent mitochondria-mediated cell death. 
These results establish an unambiguous role for BAX 
in apoptotic processes in human epithelial cancers 
and may have implications for cancer chemopreven-
tion strategies. A link between cancer and protein 
Bcl-X
L
 has already been ascribed, and there is an in-
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Table 1. Structure of new compound synthesized
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apeutic regimen for the cancer (15-16). In the present 
study, docking studies was carried out by taking pro-
teins Bcl-X
L
 (code 1YS1) (code 1BXL) (17-22), PPAR
 
receptor (code 1FM6) (23) domain as a targets for an-
ticancer activity. The docking simulations were per-
formed by the SCIGRESS program (24). Fast dock-
ing method, in which receptor is rigid and ligands 
are flexible, was adopted and binding energy values 
were compared with each other. 
All chemical structures were generated using 
ISIS DRAW 4.0 software. The docking study was 
performed using Scigress Explorer 7.7 installed in 
a single machine running on a 3.4 GHz Intel Core 
2 Duo Processor with 1GB RAM and 160 GB Hard 
Disk with Windows XP as the Operating System. Li-
gand structures 1-25 were drawn on Scigress Explor-
er using standard bond, lengths and angles. The li-
gands were stored in .csf format. The protein Bcl-XL 
and PPAR  receptor modeled using the electron crys-
tallographic structure at 3,5Å resolution was down-
loaded from the RCSB Protein Data Bank (PDB ID: 
1YS1, 1BXL and 1FM6 respectively) (www.pdb.org). 
Water molecules were removed and hydrogen added 
to crystal structure of protein before docking. After 
assigning charge and protonation state final refine-
ment (energy minimization) was done using MM3 
force field runs. At the end of the docking study, the 
minimum Consensus score for the best ligand posi-
tion for each of ligand was obtained. Energy mini-
mization or complex optimization was done for mo-
lecular docking calculations and to optimize geom-
etries within the binding site. Complex optimization 
gave ligands with minimum energy pose within the 
active site cavity of the protein.  
RESULTS 
The target protein structures of 1YS1, 1FM6, 
1BXL  were docked with new 1,2,4-triazole(4H) de-
rivatives which provided excellent results as were 
seen by the least values of the binding energy in Ta-
ble 2.
Results of docking studies have shown that uti-
lization of anilide, phuran, pyrrol, benzyl, phenoxy-
methyl, phenaminomethyl residue for the structure 
optimization of 1,2,4-triazole(4H)  scaffolds is effec-
tive approach in novel antitumor agents design and 
may be taken as the variant of hybrid pharmaco-
phore approach. Molecule 2 showed better binding 
energies than the others (highest negative dock score 
-138.229). It means that it can fit well in the receptor 
cavity (1YS1) forming energetically most stable drug 
receptor complex. The best possible binding modes 
of the 2 at targeted protein’s 1YS1active sites are dis-
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Obtained 25 heterocyclic compounds became 
an object for study concerning anticancer activity 
identifying according to the standard National Can-
cer Institute (NCI) procedure (25). The prescreen-
ing criteria became strict and the procedure of pre-
screening consists in testing of compounds activi-
ty on 60 tumor cell lines in concentration10–5 M, in-
cluding lines of leukemia, non-small cell, renal, lung 
cancer, colon cancer, CNS cancer, melanoma, ovar-
ian cancer, prostate cancer and breast cancer. Using 
the measurements (time zero, control growth, and 
test growth) in the presence of drug at the one con-
centration levels, the percentage growth was calcu-
lated. In this assay growth inhibition of 50% – GI50 
is obtained. In the screening protocol, each cell line 
was inoculated and pre-incubated for 24–48 h on a 
microtiter plate. Test agents were then added at single 
concentration and the culture was incubated for an 
additional 48 h. The end point determinations were 
made with a protein binding dye, sulforhodamine B 
(SRB). The results for each test agent were reported as 
the percent growth of the treated cells compared to 
the untreated control cells. Anticancer activity pre-
liminary screening results for tested compounds at 
one dose assay (10−5 M) are shown in Table 3. 
DISCUSSION
When analyzing the in vitro research results it 
is worth to mention that in the anticancer selectivity 
rating the most sensitive to 1,2,4-triazole(4H) deriv-
atives and related heterocyclic systems was the line 
of leukemia, non- small cell lung cancer, and pros-
tate cancer PC-3. Level of selectivity on the cell lines 
of melanoma, renal cancer and breast cancer are ap-
proximately the same. Series of cell lines, such as leu-
kemia lines (CCRF-CEM, HL-60(TB), RPMI-8226, 
SR, K-562, MOLT-4), non-small cell lung cancer 
line (HOP-92), renal cancer cell lines (UO-31), pros-
tate cancer (PC-3) and breast cancer line (MCF7) 
have been found to be the most sensitive to testing 
compounds.
Comp 1BXL 1FM6 1YS1
1 -17.043 -18.836 -77.074
2 -46.471 -51.554 -138.229
3 -50.260 -51.249 -110.468
4 -3.783 -28.531 -83.444
5 -54.238 -76.771 -118.966
6 -15.343 -27.33 -73.57
7 -44.020 -39.93 -110.769
8 -49.847 -64.502 -74.263
9 -37.330 -58.893 -101.541
10 -48.410 -39.861 -100.923
11 -42.09 -44.517 -106.040
12 -44.408 -55.730 -99.36
13 -31.212 -59.468 -113.742
14 positive positive positive
15 -28.484 -59.02 -109.123
16 positive positive positive
17 -23.371 -32.606 -48.97
18 -10.326 -22.87 -53.951
19 -51.100 -76.548 -111.195
20 31.797 -12.681 -62.831
21 -50.572 -50.369 -106.435
22 -66.029 -64.676 -61.732
23 -60.974 -38.432 -115.087
24 -58.644 -43.738 -102.839
25 positive positive positive
Table 2. Compound Dock score
Fig. 1. Dock a ligand 2 into an active site 1YS1
Fig. 2. Binding interaction of 2 with  protein.
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Among tested 1,2,4-triazole(4H) derivatives ex-
cept highly active 3,8 and 16 selected for the in-depth 
study, noteworthy is the 8, for which there was ob-
served the selective effect on leukemia and non-small 
cell lung cancer. 
Other compounds tested in one-dose primary 
assay didn’t show any impressive anticancer activity 
and therefore can’t be considered as prospective an-
ticancer agents.
Comp. Average growth, % Range of growth, % Most sensitive cancer cell lines, (growth %)
1 98.56 57.75 Prostate cancer*PC-3(75.71)
2 85.22 104.59 Leukemia*: CCRF-CEM(37.31)
Prostate cancer*PC-3(13.34)
Leukemia*:K-562 (43.96);
3 60.19 104.39 Ovarian cancer: OVCAR-4 (−7.63)
4 101. 82 57.68 Non-small cell lung cancer*: HOP-92(74.00)
5 97.32 37.57 Prostate cancer*PC-3(74.84)
6 103.48 50.14 Renal cancer*: UO-31 (71.67)
7 100.75 69.74 Colon cancer*: KM-12 (84.53)
8 56.60 138.59 Leukemia: HL-60(TB) (-16.59);
RPMI-8226(-35.98); SR (−2.07);
CCRF-СЕМ (-0.87)
Non-small cell lung cancer:
HOP-92 (-29.62)
9 98.64 52.12 Leukemia*: SR (66.63)
10 102. 96 46.95 Non-small cell lung cancer: NCL-H522(91.10)
11 98.47 40.32 Renal cancer*: UO-31 (83.52)
12 75.95 77.21 Breast cancer*T47D (30. 56)
13 86.67 80.57 Prostate cancer*PC-3(32.91)
14 90.10 47.75 Prostate cancer*PC-3(64.26)
Melanoma*: UACC-62 (68.19)
Leukemia*: MOLT-4 (62.11)
15 92.48 93.88 Prostate cancer*PC-3(25.78)
Leukemia*: CCRF-СЕМ(45.92)
16 98.49 46.30 Renal cancer*: UO-31 (71.67)
17 102. 08 44.92 Breast cancer*: T-47D (89.96)
18 106.06 29.56 Renal cancer*: UO-31 (89.72)
19 100.14 40.47 Renal cancer*: UO-31 (76.71)
20 62.13 104.57 Breast cancer MCF7 (29. 03)
21 49.34 87.87 Leukemia: SR (0.25)
Melanoma:MDA-MB-43(4.49)
22 91.27 63.69 Melanoma*:SK-MEL-5(47.82)
23 74.28 54.45 Leukemia*: K-562 (43.96)
24 102.00 143.92 Melanoma:MALME-3M(-14.85)
25 101.52 57.65 Prostate cancer*PC-3(76.33)
Table 3. Anticancer activity screening at one dose assay (10−5 M) 
* activity was not significant
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In addition, correlation studies between ex-
perimental average growth and docking scores with 
Build QSAR program were conducted (26). The cor-
relation coefficients of q2=0.38, 0.29, 0.20 between 
experimental and docking scores was obtained. The 
predictive capacity of these models is bad, taking into 
account the commonly accepted values for a satisfac-
tory QSAR model, q2 > 0.500. However, it should be 
noted that if there is docking function for Bcl-XL-
BH3 protein complex in the model, its partial con-
tribution in the PLS model is more essential, than 
if docking is performed to other biotargets. In con-
sequence of performed studies in silico it can be as-
sumed that the most probable mechanism of anti-
cancer activity of 1,2,4-triazole(4H) derivatives may 
be binding with the anti-apoptotic protein complex 
Bcl-XL-BH3.
CONCLUSIONS
Overall, this work illustrated that potential an-
ti-tumor compounds were found among new de-
rivatives 1,2,4-triazole(4H). The anticancer activi-
ty showed promising results. Compound 8 was sub-
stantially more active than others and requires fur-
ther study. The studies confirmed compound 8 as 
potent lead compound for drug discovery and fur-
ther optimization. The 8 discovered in this study 
may provide valuable therapeutic intervention for 
the treatment of cancer disease. The binding pattern 
can be further used as a tool for the structure-based 
novel anti- tumor drug design. Molecular docking 
study is used to clarify the binding mode of the me-
dicinal compound. Taken together in vitro results; 
our docking results show that there is a positive cor-
relation between the dock scores and the inhibition 
of protein Bcl-XL receptor. 
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